Buklioska Ilievska, Daniela and Mickovski, Ivana and Buklioska, Adriana (2024) Dyslipidemia in COPD Patients. In: XI International Workshop on Lung Health, 18-20 Jan 2024, Seville, Spain.
![[thumbnail of Abstract]](/style/images/fileicons/text.png) |
Text (Abstract)
AbstractBook.pdf Download (4MB) |
|
Text
Poster DYSLIPIDEMIA.pdf Download (902kB) |
Abstract
Introduction: Chronic obstructive pulmonary disease (COPD) is a progressive inflammatory lung disease that
causes obstructed airflow limitation from the lungs. COPD is currently the third leading cause of death worldwide and is characterized by airway inflammation, alveolar destruction, and airflow limitation. It is prone to
the viewpoint that systemic inflammation maybe complicated in the pathogenesis of majority comorbidities.
Material and method: The study was conducted at the General Hospital “8th September”, Skopje, in the period 2018-2020 as a continuum of our investigation of the impact of cardiovascular comorbidities on COPD.
The design is a cross-sectional study, including 220 patients with stable COPD as investigated group (IG), aged
40-75 years and 58 non-COPD subjects, matched by gender, age, BMI, smoking-status, as control group (CG).
All study subjects underwent pulmonary evaluation (dyspnea severity assessment, baseline and postbronchodilator spirometry, gas analyses), BMI measurement, laboratory analyses with attention to lipid profile (cholesterol, triglycerides, LDL = low density lipoprotein, HDL = high density lipoprotein).
Results: For p<0.05, the analysis indicated a significant difference between the four IG subgroups in terms
of triglyceride level (Kruskal-Wallis's test: H(3) =12,842; p=0.005). Analysis in IG/CG indicated an average triglyceride level of 1.34±0.74 (mmol/L) in IG vs. 1.41±0.69 (mmol/L) in CG. For p>0.05, there was no significant
difference between IG and CG respondents in relation to triglyceride value (Mann-Whitney U Test: Z=-1,484.
p=0.1377). For p>0.05, there was no significant difference between the four IG subgroups in terms of cholesterol level (Kruskal-Wallis's test: H (3) =2,303; p=0.512). Analysis in IG/CG indicated an average cholesterol value of 4.88±1.07 (mmol/l) in IG vs. 4.79±1.12 (mmol/l) in CG. For p>0.05, there was no significant difference between IG and CG subjects in relation to cholesterol levels (Mann-Whitney U Test: Z=1,187; p=0.235).
The proportion of hypercholesterolemia, hypertriglyceridemia and combination (hypercholesterolemia + hypertriglyceridemia) was consequential in - a) GOLD1 - 19 (33.33%) vs. 4 (7.02%) vs. 5 (8.77%); b) GOLD2 - 24
(38.71%) vs. 9 (14.52%) vs. 2 (3.23%); c) GOLD3 - 14 (26.92%) vs. 4 (7.69%) vs. 5 (9.62%); and d) GOLD4 - 21
(42.86%) vs. 1 (2.04%) vs. 1 (2.04%). For p>0.05, there was no significant association between the GOLD subgroup of IG, which included respondents and the dyslipidemia status for the Fisher Freeman Halton test:
p=0.190.
Conclusion: Chronic obstructive pulmonary disease - associated chronic illnesses and systemic comorbidities
pose a significant problem in the risk assessment and affect the integrated treatment plans.
| Item Type: | Conference or Workshop Item (Poster) |
|---|---|
| Subjects: | Medical and Health Sciences > Clinical medicine |
| Divisions: | Faculty of Medical Science |
| Depositing User: | Daniela Buklioska Ilievska |
| Date Deposited: | 02 Feb 2024 13:06 |
| Last Modified: | 02 Feb 2024 13:06 |
| URI: | https://eprints.ugd.edu.mk/id/eprint/33329 |
Actions (login required)
 |
View Item |